A randomized trial demonstrates comparable outcomes when switching medications in chronic hepatitis B, suggesting a viable alternative.
Switching from ETV to TAF was noninferior to continuing ETV in maintaining virologic suppression, with comparable biochemical, serologic, and safety outcomes. (ClinicalTrials. gov identifier NCT06000657).
No takes yet. Share an insight, caveat, or question.
Shin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: